Cardinal Health, Inc. - 10-K Summary (Fiscal Year Ended June 30, 1997)
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended June 30, 1997. Cardinal Health, Inc. is a leading healthcare service provider and wholesale distributor of pharmaceuticals and related products. The company operates through several key subsidiaries: Cardinal Distribution (wholesaling), Pyxis (automated medication systems), Medicine Shoppe (pharmacy franchising), Owen Healthcare (pharmacy management services), and PCI Services (packaging services). The company operates primarily in the continental United States.
Key Financial Metrics
| Metric | Fiscal 1997 | Fiscal 1996 |
|---|---|---|
| Net Revenues | $10,968,042,000 | $9,246,420,000 |
| Gross Margin | $904,958,000 (8.25%) | $773,234,000 (8.36%) |
| Operating Earnings | $334,378,000 | $226,544,000 |
| Net Earnings | $181,119,000 | $117,634,000 |
| Diluted EPS | $1.66 | $1.14 |
| Total Assets | $3,108,546,000 | $2,825,175,000 |
| Long-Term Obligations | $277,766,000 | $265,146,000 |
| Working Capital | $1,095,000,000 | $924,400,000 |
| Cash and Equivalents | $243,061,000 | $304,281,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 19% to $10.97 billion, driven by internal growth in pharmaceutical distribution, new customer additions (notably an expanded relationship with Kmart), and increased volume from existing customers.
- Profitability: Net earnings rose 54% to $181.1 million. Operating earnings increased significantly to $334.4 million.
- Margins: Gross margin percentage decreased slightly to 8.25% from 8.36% due to a shift in revenue mix toward lower-margin distribution activities. However, Selling, General, and Administrative (SG&A) expenses improved as a percentage of revenue to 4.68% from 5.19% due to economies of scale and cost controls.
- Merger Costs: The company incurred $56.96 million in merger-related costs in fiscal 1997 (down from $67.25 million in 1996), primarily related to the acquisitions of Owen Healthcare and PCI Services. These costs reduced net earnings by approximately $40.2 million.
- Liquidity: Working capital increased by $170.6 million. Cash and equivalents decreased by $61.2 million, largely due to increased investments in merchandise inventories ($180.1 million increase) and trade receivables ($59.9 million increase) to support business volume.
Guidance, Outlook, and Risks
- Pending Acquisitions:
- MediQual Systems: Agreed to a stock-for-stock merger (pooling-of-interests) expected to close in the first half of fiscal 1998. Estimated issuance of 0.6 million shares.
- Bergen Brunswig: Agreed to a merger on August 23, 1997. Cardinal will issue approximately 40 million shares and assume $386 million in long-term debt. Expected to close by the end of the third quarter of fiscal 1998.
- Legal Proceedings: The company is a defendant in consolidated antitrust litigation ("Brand Name Prescription Drug Litigation") alleging price-fixing via chargeback systems. A summary judgment previously granted in the company's favor was reversed by the Court of Appeals in August 1997. The company intends to contest vigorously but does not believe the outcome will have a material adverse effect.
- Customer Concentration: Kmart Corporation accounted for approximately 13% of net revenues in fiscal 1997. The loss of this customer could adversely affect the business.
- Regulatory Risks: Operations are subject to strict regulation by the FDA, DEA, and state boards of pharmacy. Changes in regulations regarding automated dispensing systems or franchise laws could impact operations.
Investor Verification Checklist
- Merger Integration: Verify the actual costs and synergies realized from the recent acquisitions of Owen Healthcare and PCI Services against the estimated merger costs of $57 million.
- Bergen Brunswig Merger: Monitor the regulatory approval process and shareholder votes for the Bergen Brunswig merger, specifically the assumption of $386 million in debt.
- Antitrust Litigation: Track the status of the "Brand Name Prescription Drug Litigation" appeal and any potential financial exposure.
- Kmart Dependency: Assess the stability of the relationship with Kmart, which represents a significant portion (13%) of total revenue.
- Inventory Management: Review the $180 million increase in merchandise inventories to ensure it aligns with sales velocity and does not lead to future write-downs.